印度接近Dengiall(一种单剂量登革热疫苗)的最后测试,可能到2027年得到批准。 India nears final testing of DengiAll, a single-dose dengue vaccine, with potential approval by 2027.

印度正处于测试Deniall的最后阶段,Deniall是一种由Panacea Biotec研制的单剂量登革热疫苗,全国有10 000多人参加试验。 India is in the final phase of testing DengiAll, a single-dose dengue vaccine developed by Panacea Biotec, with trials involving over 10,000 participants nationwide. 该疫苗以美国NIH派生的四价菌株为基础,研制了15年,旨在预防所有四种登革热血清型。 The vaccine, based on a U.S. NIH-derived tetravalent strain and developed over 15 years, aims to protect against all four dengue serotypes. 随着全球登革热病例的上升,特别是在印度,自2021年以来,印度有100多万人感染登革热,1 500人死亡。 成功的试验结果可能导致印度到2027年批准登革热,使其成为全世界最早供应的单剂量疫苗之一。 With dengue cases rising globally—especially in India, which has seen over one million infections and 1,500 deaths since 2021—successful trial results could lead to approval in India by 2027, making it one of the first single-dose vaccines available worldwide. 最后的核准取决于印度药品管制总长和卫生组织的全球使用资格预审。 Final approval depends on India’s Drug Controller General and WHO prequalification for global use. 专家们强调,只有第三阶段的成果才能证实安全性和有效性,但进展为受该疾病影响最严重的地区提供更便捷、更廉价的解决办法带来了希望。 Experts stress that only Phase III results will confirm safety and efficacy, but the progress offers hope for a more accessible, affordable solution in regions hardest hit by the disease.